Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2018 08:28 ET | Source: Genmab A/S

CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Front Line Multiple Myeloma

Company Announcement CHMP issued positive opinion for DARZALEX for front line multiple myelomaFinal decision from European Commission expected in the coming monthsOpinion based on...
July 17, 2018 06:50 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2018

Company Announcement Net sales of DARZALEX in the second quarter of 2018 totaled USD 511 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. ...
July 12, 2018 01:56 ET | Source: Genmab A/S

Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies

Company Announcement Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT® technologyCreation of novel...
July 03, 2018 12:45 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; July 3, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 24,025 shares as a consequence of the exercise of...
June 29, 2018 10:19 ET | Source: Genmab A/S

HuMax®-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics

Company Announcement Genmab to pay Seattle Genetics, Inc. a milestone payment of USD 7 million under the Antibody-Drug Conjugate (ADC) program targeting AXL Milestone triggered...
June 07, 2018 14:31 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Genmab employees

Company Announcement Copenhagen, Denmark; June 7, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 5,305 restricted stock units and 14,714...
May 29, 2018 10:38 ET | Source: Genmab A/S

Genmab to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

Media Release Copenhagen, Denmark; May 29, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the...
May 26, 2018 03:55 ET | Source: Genmab A/S

Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1

Company Announcement Based on a recent planned review, the Data Monitoring Committee (DMC) recommends Phase Ib/II study of daratumumab plus atezolizumab (anti PD-L1 antibody) in patients with...
May 24, 2018 10:20 ET | Source: Genmab A/S

Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma

Company Announcement Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Copenhagen, Denmark; May 24, 2018 – Genmab A/S...
May 17, 2018 10:19 ET | Source: Genmab A/S

Genmab Announces Abstracts to be Presented at 23rd EHA Annual Congress

Media Release Seven industry sponsored abstracts regarding Genmab programs scheduled for presentation at EHA Annual CongressTwo oral presentations, five poster presentations ...